Alkermes plc (NASDAQ:ALKS – Free Report) – Equities researchers at Zacks Research lifted their Q1 2026 earnings estimates for Alkermes in a research report issued on Wednesday, October 9th. Zacks Research analyst R. Department now expects that the company will post earnings of $0.43 per share for the quarter, up from their prior estimate of $0.42. The consensus estimate for Alkermes’ current full-year earnings is $2.36 per share.
Alkermes (NASDAQ:ALKS – Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The company reported $0.70 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.70. Alkermes had a net margin of 19.15% and a return on equity of 23.20%. The company had revenue of $399.13 million during the quarter, compared to analysts’ expectations of $393.30 million. During the same quarter in the previous year, the company earned $0.38 earnings per share. The firm’s revenue for the quarter was down 35.4% on a year-over-year basis.
Read Our Latest Analysis on Alkermes
Alkermes Stock Up 5.6 %
ALKS opened at $28.91 on Friday. Alkermes has a fifty-two week low of $22.01 and a fifty-two week high of $32.88. The company has a debt-to-equity ratio of 0.22, a quick ratio of 2.61 and a current ratio of 2.99. The company has a fifty day moving average of $27.59 and a two-hundred day moving average of $25.78. The stock has a market capitalization of $4.89 billion, a price-to-earnings ratio of 11.43, a PEG ratio of 0.56 and a beta of 0.46.
Institutional Trading of Alkermes
Several large investors have recently bought and sold shares of the business. Signaturefd LLC boosted its holdings in Alkermes by 51.2% in the 2nd quarter. Signaturefd LLC now owns 1,417 shares of the company’s stock valued at $34,000 after purchasing an additional 480 shares during the last quarter. Hexagon Capital Partners LLC lifted its holdings in shares of Alkermes by 3,841.0% in the 2nd quarter. Hexagon Capital Partners LLC now owns 1,537 shares of the company’s stock worth $37,000 after acquiring an additional 1,498 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Alkermes by 44.4% in the 2nd quarter. GAMMA Investing LLC now owns 2,287 shares of the company’s stock worth $55,000 after acquiring an additional 703 shares during the last quarter. CWM LLC lifted its holdings in shares of Alkermes by 36.7% in the 1st quarter. CWM LLC now owns 2,732 shares of the company’s stock worth $74,000 after acquiring an additional 733 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of Alkermes in the 2nd quarter worth approximately $116,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Further Reading
- Five stocks we like better than Alkermes
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What is a SEC Filing?
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What is the S&P 500 and How It is Distinct from Other Indexes
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.